27434049|t|Changes in Cardiovascular Health Status and the Risk of New-Onset Hypertension in Kailuan Cohort Study
27434049|a|American Heart Association cardiovascular health metrics are intimately related to cardiovascular diseases. Acting as a key independent risk factor for high morbidity and mortality of cardiovascular diseases, hypertension and its relationship between health status get urgent attention. While the influence of individual health status changes and the future risk of new-onset hypertension is rarely understood, the present study applied this construct to assess the changes of cardiovascular health status and the morbidity of hypertension in Kailuan cohort study in north China. The Cardiovascular Health Score (CHS) was evaluated by the follow-ups of 2006-2007, 2008-2009, 2010-2011 and 2012-2013. The study population (n = 19381) was divided into 5 groups based on the changes in their CHS score between the first two follow-ups (△CHS) of 2006-2007 and 2008-2009 (≤-2, -1, 0, 1, ≥2). The morbidity of hypertension was collected during 2010-2011 and 2012-2013 follow-ups. Data analysis showed that during a median follow-up of 3.79±0.96 years, morbidity of hypertension had a graded relationship with △CHS. As △CHS scored from low to high, the standardized morbidity of hypertension for all participants were 81.40, 75.47, 68.37, 71.43 and 83.13 per 1000 person-year, respectively. An increased △CHS score of 1 was associated with a 10% decrease in the future risk of new-onset hypertension (HR: 0.90, 95% CI: 0.88-0.92). In conclusion, there was a strong inverse relationship between the incidence of new-onset hypertension and elevation of cardiovascular health metrics. Population -wide prevention, especially the promotion of lifestyle improvements, is critical to reducing the morbidity of new-onset hypertension.
27434049	0	7	Changes	T169	C0392747
27434049	11	25	Cardiovascular	T029	C3887460
27434049	26	39	Health Status	T080	C0018759
27434049	48	55	Risk of	T078	C0035647
27434049	56	78	New-Onset Hypertension	UnknownType	C0745129
27434049	82	89	Kailuan	T098	C1257890
27434049	90	102	Cohort Study	T081	C0009247
27434049	103	129	American Heart Association	T093	C0002458
27434049	130	144	cardiovascular	T029	C3887460
27434049	145	159	health metrics	T170	C0282574
27434049	186	209	cardiovascular diseases	T047	C0007222
27434049	223	226	key	T080	C3898777
27434049	239	250	risk factor	T033	C0035648
27434049	255	259	high	T080	C0205250
27434049	260	269	morbidity	T081	C0026538
27434049	274	283	mortality	T081	C0681679
27434049	287	310	cardiovascular diseases	T047	C0007222
27434049	312	324	hypertension	T047	C0020538
27434049	333	345	relationship	T080	C0439849
27434049	354	367	health status	T080	C0018759
27434049	379	388	attention	T041	C0004268
27434049	400	409	influence	T077	C4054723
27434049	413	423	individual	T098	C0027361
27434049	424	437	health status	T080	C0018759
27434049	438	445	changes	T169	C0392747
27434049	461	468	risk of	T078	C0035647
27434049	469	491	new-onset hypertension	UnknownType	C0745129
27434049	558	564	assess	T058	C0184514
27434049	569	576	changes	T169	C0392747
27434049	580	594	cardiovascular	T029	C3887460
27434049	595	608	health status	T080	C0018759
27434049	617	626	morbidity	T081	C0026538
27434049	630	642	hypertension	T047	C0020538
27434049	646	653	Kailuan	T098	C1257890
27434049	654	666	cohort study	T081	C0009247
27434049	670	675	north	T082	C1709269
27434049	676	681	China	T083	C0008115
27434049	687	701	Cardiovascular	T029	C3887460
27434049	702	714	Health Score	T081	C0449820
27434049	716	719	CHS	T081	C0449820
27434049	725	734	evaluated	T058	C0220825
27434049	742	752	follow-ups	T058	C3274571
27434049	807	823	study population	T098	C2348561
27434049	840	847	divided	T169	C0332849
27434049	855	861	groups	T078	C0441833
27434049	875	882	changes	T169	C0392747
27434049	892	901	CHS score	T081	C0449820
27434049	924	934	follow-ups	T058	C3274571
27434049	994	1003	morbidity	T081	C0026538
27434049	1007	1019	hypertension	T047	C0020538
27434049	1024	1033	collected	T169	C1516698
27434049	1034	1040	during	T079	C0347984
27434049	1065	1075	follow-ups	T058	C3274571
27434049	1077	1090	Data analysis	T057	C0010992
27434049	1103	1109	during	T079	C0347984
27434049	1112	1118	median	T081	C0876920
27434049	1119	1128	follow-up	T058	C3274571
27434049	1149	1158	morbidity	T081	C0026538
27434049	1162	1174	hypertension	T047	C0020538
27434049	1188	1200	relationship	T080	C0439849
27434049	1249	1261	standardized	T058	C1255664
27434049	1262	1271	morbidity	T081	C0026538
27434049	1275	1287	hypertension	T047	C0020538
27434049	1296	1308	participants	T098	C0679646
27434049	1390	1399	increased	T081	C0205217
27434049	1442	1450	decrease	T081	C0547047
27434049	1458	1464	future	T079	C0016884
27434049	1465	1472	risk of	T078	C0035647
27434049	1473	1495	new-onset hypertension	UnknownType	C0745129
27434049	1511	1513	CI	T081	C0009667
27434049	1569	1581	relationship	T080	C0439849
27434049	1607	1629	new-onset hypertension	UnknownType	C0745129
27434049	1634	1643	elevation	T080	C3163633
27434049	1647	1661	cardiovascular	T029	C3887460
27434049	1662	1676	health metrics	T170	C0282574
27434049	1678	1688	Population	T098	C1257890
27434049	1695	1705	prevention	T080	C2700409
27434049	1722	1731	promotion	T058	C0018738
27434049	1735	1744	lifestyle	T054	C0023676
27434049	1745	1757	improvements	T077	C2986411
27434049	1762	1770	critical	T080	C1511545
27434049	1774	1782	reducing	T080	C0392756
27434049	1787	1796	morbidity	T081	C0026538
27434049	1800	1822	new-onset hypertension	UnknownType	C0745129